Anna Li, Wei-Neng Feng, Juan Li, Bing-Fei Xu, Jun Zhao, Yun Jia, Ke-Jing Tang, Yong-Sheng Li, Cheng-Zhi Zhou, Yun Fan, Chong-Rui Xu, Yue-Li Sun, Hua-Jun Chen, Hong-Hong Yan, Zong-Kun Shi, Jin-Ji Yang. "Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)." Nature Communications, 2026. doi:10.1038/s41467-025-67950-8